TORONTO and CAMBRIDGE, MA, Dec. 4, 2017 /PRNewswire/ – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (…
